vs
Adaptive Biotechnologies Corp（ADPT）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
Adaptive Biotechnologies Corp的季度营收约是READING INTERNATIONAL INC的1.4倍（$71.7M vs $50.3M），READING INTERNATIONAL INC净利率更高（-5.1% vs -18.9%，领先13.8%），Adaptive Biotechnologies Corp同比增速更快（51.0% vs -14.2%），READING INTERNATIONAL INC自由现金流更多（$4.1M vs $1.4M），过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs 5.6%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
ADPT vs RDI — 直观对比
营收规模更大
ADPT
是对方的1.4倍
$50.3M
营收增速更快
ADPT
高出65.2%
-14.2%
净利率更高
RDI
高出13.8%
-18.9%
自由现金流更多
RDI
多$2.7M
$1.4M
两年增速更快
ADPT
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $50.3M |
| 净利润 | $-13.6M | $-2.6M |
| 毛利率 | 74.6% | — |
| 营业利润率 | -17.8% | -1.9% |
| 净利率 | -18.9% | -5.1% |
| 营收同比 | 51.0% | -14.2% |
| 净利润同比 | 59.7% | -14.5% |
| 每股收益（稀释后） | $-0.08 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTRDI
| Q4 25 | $71.7M | $50.3M | ||
| Q3 25 | $94.0M | $52.2M | ||
| Q2 25 | $58.9M | $60.4M | ||
| Q1 25 | $52.4M | $40.2M | ||
| Q4 24 | $47.5M | $58.6M | ||
| Q3 24 | $46.4M | $60.1M | ||
| Q2 24 | $43.2M | $46.8M | ||
| Q1 24 | $41.9M | $45.1M |
净利润ADPTRDI
| Q4 25 | $-13.6M | $-2.6M | ||
| Q3 25 | $9.5M | $-4.2M | ||
| Q2 25 | $-25.6M | $-2.7M | ||
| Q1 25 | $-29.9M | $-4.8M | ||
| Q4 24 | $-33.7M | $-2.2M | ||
| Q3 24 | $-32.1M | $-7.0M | ||
| Q2 24 | $-46.2M | $-12.8M | ||
| Q1 24 | $-47.5M | $-13.2M |
毛利率ADPTRDI
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
营业利润率ADPTRDI
| Q4 25 | -17.8% | -1.9% | ||
| Q3 25 | 10.9% | -0.6% | ||
| Q2 25 | -42.5% | 4.8% | ||
| Q1 25 | -56.4% | -17.2% | ||
| Q4 24 | -71.3% | 2.6% | ||
| Q3 24 | -70.3% | -0.6% | ||
| Q2 24 | -109.6% | -16.4% | ||
| Q1 24 | -116.5% | -16.7% |
净利率ADPTRDI
| Q4 25 | -18.9% | -5.1% | ||
| Q3 25 | 10.2% | -8.0% | ||
| Q2 25 | -43.5% | -4.4% | ||
| Q1 25 | -56.9% | -11.8% | ||
| Q4 24 | -71.0% | -3.8% | ||
| Q3 24 | -69.1% | -11.7% | ||
| Q2 24 | -107.0% | -27.4% | ||
| Q1 24 | -113.5% | -29.4% |
每股收益（稀释后）ADPTRDI
| Q4 25 | $-0.08 | $-0.11 | ||
| Q3 25 | $0.06 | $-0.18 | ||
| Q2 25 | $-0.17 | $-0.12 | ||
| Q1 25 | $-0.20 | $-0.21 | ||
| Q4 24 | $-0.22 | $-0.11 | ||
| Q3 24 | $-0.22 | $-0.31 | ||
| Q2 24 | $-0.31 | $-0.57 | ||
| Q1 24 | $-0.33 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $10.5M |
| 总债务越低越好 | — | $185.1M |
| 股东权益账面价值 | $218.8M | $-18.2M |
| 总资产 | $512.7M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ADPTRDI
| Q4 25 | $70.5M | $10.5M | ||
| Q3 25 | $55.0M | $8.1M | ||
| Q2 25 | $43.2M | $9.1M | ||
| Q1 25 | $50.6M | $5.9M | ||
| Q4 24 | $47.9M | $12.4M | ||
| Q3 24 | $38.1M | $10.1M | ||
| Q2 24 | $59.8M | $9.3M | ||
| Q1 24 | $71.2M | $7.5M |
总债务ADPTRDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADPTRDI
| Q4 25 | $218.8M | $-18.2M | ||
| Q3 25 | $204.4M | $-12.1M | ||
| Q2 25 | $179.7M | $-7.7M | ||
| Q1 25 | $190.4M | $-8.1M | ||
| Q4 24 | $202.7M | $-4.4M | ||
| Q3 24 | $223.8M | $1.6M | ||
| Q2 24 | $241.6M | $6.5M | ||
| Q1 24 | $274.9M | $18.0M |
总资产ADPTRDI
| Q4 25 | $512.7M | $434.9M | ||
| Q3 25 | $490.6M | $435.2M | ||
| Q2 25 | $496.6M | $438.1M | ||
| Q1 25 | $510.9M | $441.0M | ||
| Q4 24 | $539.4M | $471.0M | ||
| Q3 24 | $558.5M | $495.7M | ||
| Q2 24 | $584.9M | $494.9M | ||
| Q1 24 | $620.3M | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | $4.1M |
| 自由现金流率自由现金流/营收 | 2.0% | 8.2% |
| 资本支出强度资本支出/营收 | 0.9% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-48.9M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流ADPTRDI
| Q4 25 | $2.1M | $4.3M | ||
| Q3 25 | $-7.1M | $295.0K | ||
| Q2 25 | $-12.4M | $1.6M | ||
| Q1 25 | $-28.5M | $-7.7M | ||
| Q4 24 | $-12.5M | $8.0M | ||
| Q3 24 | $-27.1M | $1.3M | ||
| Q2 24 | $-17.3M | $-10.4M | ||
| Q1 24 | $-38.4M | $-2.8M |
自由现金流ADPTRDI
| Q4 25 | $1.4M | $4.1M | ||
| Q3 25 | $-7.5M | $-246.0K | ||
| Q2 25 | $-13.1M | $1.2M | ||
| Q1 25 | $-29.7M | $-8.0M | ||
| Q4 24 | $-12.6M | $7.0M | ||
| Q3 24 | $-27.4M | $-1.1M | ||
| Q2 24 | $-19.0M | $-10.6M | ||
| Q1 24 | $-39.9M | $-4.7M |
自由现金流率ADPTRDI
| Q4 25 | 2.0% | 8.2% | ||
| Q3 25 | -8.0% | -0.5% | ||
| Q2 25 | -22.2% | 1.9% | ||
| Q1 25 | -56.7% | -19.8% | ||
| Q4 24 | -26.5% | 12.0% | ||
| Q3 24 | -59.0% | -1.8% | ||
| Q2 24 | -44.1% | -22.7% | ||
| Q1 24 | -95.2% | -10.4% |
资本支出强度ADPTRDI
| Q4 25 | 0.9% | 0.3% | ||
| Q3 25 | 0.4% | 1.0% | ||
| Q2 25 | 1.1% | 0.6% | ||
| Q1 25 | 2.4% | 0.6% | ||
| Q4 24 | 0.2% | 1.7% | ||
| Q3 24 | 0.7% | 4.0% | ||
| Q2 24 | 4.0% | 0.5% | ||
| Q1 24 | 3.6% | 4.3% |
现金转化率ADPTRDI
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
